Rafferty Asset Management LLC lowered its holdings in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 35.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 136,417 shares of the company's stock after selling 74,539 shares during the period. Rafferty Asset Management LLC owned approximately 0.16% of Verve Therapeutics worth $769,000 as of its most recent SEC filing.
Several other hedge funds have also recently added to or reduced their stakes in VERV. Nisa Investment Advisors LLC raised its stake in Verve Therapeutics by 465.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 42,781 shares of the company's stock valued at $241,000 after acquiring an additional 35,214 shares in the last quarter. Impact Partnership Wealth LLC bought a new stake in Verve Therapeutics during the 4th quarter valued at $70,000. China Universal Asset Management Co. Ltd. raised its stake in Verve Therapeutics by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,952 shares of the company's stock valued at $101,000 after acquiring an additional 1,676 shares in the last quarter. Rhumbline Advisers raised its stake in Verve Therapeutics by 1.9% during the 4th quarter. Rhumbline Advisers now owns 111,203 shares of the company's stock valued at $627,000 after acquiring an additional 2,093 shares in the last quarter. Finally, IFP Advisors Inc raised its stake in Verve Therapeutics by 823,700.0% during the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company's stock valued at $47,000 after acquiring an additional 8,237 shares in the last quarter. Institutional investors own 97.11% of the company's stock.
Verve Therapeutics Stock Performance
Shares of VERV stock opened at $4.38 on Friday. Verve Therapeutics, Inc. has a 1 year low of $2.86 and a 1 year high of $9.31. The stock has a market cap of $390.45 million, a PE ratio of -1.78 and a beta of 1.82. The business's fifty day moving average is $4.64 and its 200-day moving average is $5.82.
Verve Therapeutics (NASDAQ:VERV - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.36. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The company had revenue of $32.98 million for the quarter, compared to analysts' expectations of $7.13 million. Equities research analysts predict that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.
Analyst Ratings Changes
Several analysts have weighed in on the company. Guggenheim lifted their target price on Verve Therapeutics from $18.00 to $24.00 and gave the company a "buy" rating in a research note on Tuesday, April 15th. HC Wainwright lifted their target price on Verve Therapeutics from $15.00 to $25.00 and gave the company a "buy" rating in a research note on Monday, April 14th. Cantor Fitzgerald raised Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Tuesday, April 15th. William Blair reiterated an "outperform" rating on shares of Verve Therapeutics in a research report on Friday, February 21st. Finally, Canaccord Genuity Group lifted their price target on Verve Therapeutics from $32.00 to $39.00 and gave the company a "buy" rating in a research report on Tuesday, April 15th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $25.75.
Check Out Our Latest Stock Analysis on VERV
Verve Therapeutics Company Profile
(
Free Report)
Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.
See Also
Want to see what other hedge funds are holding VERV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Verve Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verve Therapeutics wasn't on the list.
While Verve Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
